Blocking Dkk‑1 to fight osteosarcoma using insights from pet dogs
Official title: A Dkk-1 targeting antisense therapy for human osteosarcoma, developed with help from man’s best friend
Funded at Texas A&m University Health Science Ctr · NIH-11251622 · Data updated 2026-11-12
A gene‑targeting antisense drug that blocks the protein Dkk‑1 is being developed to help people (including children) with osteosarcoma.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2026 |
| Funding year | 2026 |
| Award (this year) | $175,929 |
| NIH project number | 5R21CA286523-02 |
| Project ID | NIH-11251622 on NIH RePORTER |
Who could benefit from this research
✓Could help
People diagnosed with osteosarcoma—especially pediatric cases or those whose tumors produce Dkk‑1—would be the intended beneficiaries and candidates for future trials.
✕Less likely to help
Patients whose tumors do not rely on Dkk‑1 or who have other cancer types are unlikely to benefit from this specific therapy.
What this research studies
Researchers are developing an antisense molecule that stops tumors from making Dkk‑1, a protein linked to bone damage and cancer spread. In mice, a Dkk‑1 blocker reduced bone destruction, slowed tumor growth, and lowered lung metastases, and a dog‑specific version (cDkkMo) has been made. Because canine osteosarcoma closely resembles the human disease, the team plans veterinary trials in pet dogs at Texas A&M to study safety and effectiveness. Cell culture, mouse models, and client‑owned dogs will be used to gather data that could support future human trials.
Why it matters
Potential benefit: If successful, this approach could reduce bone damage, slow tumor growth, and lower metastatic spread in osteosarcoma, improving survival and quality of life.
How similar studies have gone: Preclinical mouse studies showed promising tumor and bone‑protective effects of Dkk‑1 blockade, but translating this to dogs and humans is a novel step.
Where this research is happening
-
Texas A&m University Health Science Ctr
College Station, United States Active
Researchers
- Principal investigator: Gregory, Carl a. — Texas A&m University Health Science Ctr
- Study coordinator: Gregory, Carl a.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how bone cancer cells rely on certain pathways to grow in childhood osteosarcoma
This grant studies how specific cancer-related pathways in bone-forming cells drive osteosarcoma in children, with the aim of finding better treatments.
-
Histotripsy + immune boost to fight osteosarcoma
A new treatment idea combines a precise non-surgical ultrasound method with an immune-boosting compound to help fight bone cancer in people and dogs.
-
Genomically guided drug testing for osteosarcoma in patient-derived models
A precision approach tests new drugs on osteosarcoma models created from patients to find promising treatments for kids and teens.
-
New ways to stop osteosarcoma from spreading
Researchers are testing new approaches to block how osteosarcoma spreads, with the aim of improving survival for children and adults with metastatic disease.
-
Targeting OST Redundancy to Treat Osteosarcoma
A study in people with advanced bone cancer to see if new OST-targeting drugs can slow or stop tumor growth.
-
Focal Adhesion Kinase inhibitor to block osteosarcoma spread to the lungs
A cancer treatment plan tests whether blocking a specific cell signal can stop osteosarcoma from growing and spreading to the lungs in kids and young people.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.